SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: contrarian who wrote (1464)2/2/1998 2:40:00 AM
From: Roger Cranwill  Respond to of 1762
 
Whoa, fellas, I hope you're not expecting good earnings in IDEC's 4th quarter-2 weeks of sales in that quarter won't cut it, and the way the stock's been going up, I think some people are in for a rude awakening. First quarter results are ones to look forward to...Roger



To: contrarian who wrote (1464)2/2/1998 10:58:00 AM
From: Roudy  Read Replies (1) | Respond to of 1762
 
If I remember correctly, I believe IDEC had Rituxan manufactured and available for the anticipated pent up demand. They also had set up a new manufacturing facility last year in anticipation of the approval of Rituxan. From previous posts and inquiries the response was, this would not be a problem. However, I will have to check with IR to be sure.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News